|
|
Cardium Therapeutics Post-Effective Amendment No. 1 to Resale Registration Statement Declared Effective
SAN DIEGO, May 12, 2006 -- Cardium Therapeutics, Inc. (OTC: CDTP) announced today that Post-Effective Amendment No. 1 to its Registration Statement on Form SB-2 was declared effective by the Securities and Exchange Commission on May 12, 2006. The registration statement, which was updated to reflect the Company's recent acquisition of InnerCool Therapies, Inc., registers the resale of Cardium common stock by the selling stockholders named in the registration statement. Selling stockholders included in the resale registration statement may obtain a copy of the prospectus relating to their shares of Cardium common stock by contacting the Company's Director of Investor Relations at (858) 436-1018 or via mail at InvestorRelations@cardiumthx.com. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. About Cardium Cardium Therapeutics, Inc., founded in 2003 and headquartered in San Diego, is a medical technology company primarily focused on the development, manufacture and sale of innovative therapeutic products for cardiovascular and related indications. In October 2005, Cardium acquired a portfolio of growth factor therapeutics from the Schering AG Group, Germany, including the later-stage product candidate, Generx™, and completed a $30 million financing. Generx (alferminogene tadenovec) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. As announced in March 2006, Cardium has also acquired the technologies and products of InnerCool Therapies, Inc., a San Diego-based medical technology company in the emerging field of therapeutic hypothermia, which is designed to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurologic outcomes. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia, including its Celsius Control System™, which has now received regulatory clearance in the U.S., Europe and Australia, please visit www.innercool.com. For more information about Cardium and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com. Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the effectiveness of a resale registration statement will increase investor participation or volume, that required clinical trials will be successful, that necessary regulatory approvals will be obtained, or that the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of DNA-based cardiovascular therapeutics, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings made by us with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. Copyright 2006 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use, please visit www.cardiumthx.com. Cardium Therapeutics™ and Generx™ are trademarks of Cardium Therapeutics, Inc. InnerCool Therapies®, Innercool®, and Celsius Control System™ are trademarks of InnerCool Therapies, Inc. Press/Investors, Bonnie Ortega, Director, Investor/Public Relations of Cardium Therapeutics, Inc., +1-858-436-1018, investorRelations@cardiumthx.com Source: Cardium Therapeutics, Inc. |
Angioplasty.Org Home • PatientCenter
this press release is posted as a reader
service by Angioplasty.org,
an editorially independent informational health
site
which has received unrestricted educational grants from
Medtronic plc,
TCROSS NEWS, Toshiba
America
Medical Systems, Volcano
Corporation, Terumo
Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021
